Aptar Pharma range of rigid needle shields, vial stoppers, pre-filled syringe and cartridge plungers, for GLP1 applications.

Pre-Filled Syringe, Autoinjector And Pen Injector Solutions For GLP-1 Applications

Glucagon-like peptide-1 (GLP-1) treatments have demonstrated remarkable effectiveness in addressing major public health issues, including diabetes and obesity.

Accelerate and derisk your GLP-1 drug development programs with Aptar Pharma’s reliable packaging solutions, including rigid needle shields (RNS), pre-filled syringe (PFS) and cartridge plungers. Our advanced parenteral closure solutions help optimize and secure your fill-finish operations.

Accelerate And Derisk The Development Of Your GLP-1 Drugs For Diabetes And Obesity Treatments

Platform of pre-filled system components

Glucagon-like peptide-1 (GLP-1) based self-injection drugs for type 2 diabetes and obesity often rely on autoinjectors or pen injector systems to ensure their safe and effective administration by patients.

Aptar Pharma offers a range of high-quality components to support your GLP-1 product development needs:

  • Pre-filled syringe (PFS) plungers
  • Rigid needle shields (RNS)
  • Cartridge plungers for pen-injectors 

Take your development from formulation to patient with Aptar Pharma’s drug development services, innovative solutions and patient services that support the success of your self-injected GLP-1 drug products for diabetes and obesity.

Ensure your long-term security of supply of GLP-1 injectable components

With a growing market for diabetes and obesity treatments, securing your long-term security of supply of GLP-1 self-injection components is essential. We continue to expand our injectable component manufacturing capabilities, leveraging robotization and clean room manufacturing capacity to ensure you receive ever-increasing quality worldwide.

With a new factory in Europe, new manufacturing lines in the US and worldwide upgrade plans, we are investing in capabilities to support your drug developments needs and transform your expectations of what an injectable partner should be.

Accelerate and derisk your GLP-1 drug and delivery device development

When developing glucagon-like peptide-1 (GLP-1) drugs, such as for diabetes or obesity, the compatibility of the formulation with the primary container is a major concern that could potentially delay regulatory approval.

Leverage Aptar Pharma’s pure rubber component formulation, market proven component designs and clean room manufacturing capabilities to promote drug to component compatibility. For your most sensitive drug development programs, choose PremiumCoat® ETFE film-coated plungers to further reduce the risks related to extractables, and leachables.

Facilitate your choice of primary packaging

Selecting the right primary packaging partner is essential to derisk your regulatory review and reduce time-to-market. World-leading glass-manufacturing and pharmaceutical companies have already validated our pre-filled syringe component solutions and are partnering with us to develop self-injection devices for glucagon-like peptide-1 (GLP-1) and a wide range of other applications.

Support your brand image and differentiate your GLP-1 drug

As GLP-1 drugs are getting more attention and global competition increases, differentiation will become essential for the success of your injectable drug. Customize your parenteral drug delivery solutions with us, meeting your specific requirements and supporting your brand image.

Product Details

Contact Aptar Pharma’s Parenteral Expert Team Today

Learn more about how we can support your compliance with EMA GMP Annex 1 revisions and optimize your operations with our advanced injectable packaging solutions.

REQUEST MORE INFORMATION

Recently Published Resources

24 Oct 2018

Good Medicine: Solutions for Sensitive Injectable Formulations

Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Market Insights

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 May 2018

Pharma Partnering Considerations for Injectable Device Components

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 12 13 14